Programme 2021 | Global Congress on Prostate and Bladder Cancer

Preliminary programme

For 2021, our focus remains: turning new data into your daily practice. The programme will consist of state-of-the-art lectures, case discussions and panel debates. Our faculty is a group of international & multidisciplinary experts.

We will take you on our journey to Ghent and beyond. Prior the congress, we send out case challenges, where you can compare your opinion with peers & experts. These cases will be part of the Global Congresses on Prostate & Bladder Cancer programme during the congress days (12 & 13 October for PROSCA and 14 & 15 October for BLADDR). After these days, you will be updated on prostate & bladder cancer management.

PROSCA

12 & 13 October 2021

BLADDR

14 & 15 October 2021

PROSCA

12 & 13 October 2021

BLADDR

14 & 15 October 2021

Legend:
Lecture
Debate/ panel discussion
Q&A

PROSCA 2021

Day 1 – 12 October 2021

Official opening
Session 1
Metastatic HSPC
Selecting treatment in daily clinical practice

Can we extrapolate evidence acquired on standard imaging to patients diagnosed by PSMA-PET/CT?

How to interpret subgroup analyses? Insights from the statistician

 

Debate: Metastasis-directed therapy: when, how, for who?

Q&A
Session 2
Managing localised prostate cancer

Is ePLND still required in PSMA-PET/CT negative patients?

What is the role of focal therapy in PCa?

The evolving role of RT in localised PCa

Q&A
Session 3
Broadening horizons in the management of CRPC
Genomic testing in advanced PCa: a pragmatic guide for clinicians
Where does Lu-PSMA fit in the treatment landscape?
How to deal with the conundrum of the 3rd line?
New agents on the horizon
Q&A
Best poster session
Session 4
Interpretation of novel imaging for clinicians
Reading MRI for non-radiologists

Improve your PSMA-PET/CT reading skills

Q&A

PROSCA 2021

Day 1 – 12 October 2021

Official opening
Metastatic HSPC
Selecting treatment in daily clinical practice
Can we extrapolate evidence acquired on standard imaging to patients diagnosed by PSMA-PET/CT?
How to interpret subgroup analyses? Insights from the statistician
Debate: Metastasis-directed therapy: when, how, for who?
Q&A
Managing localised prostate cancer
Is ePLND still required in PSMA-PET/CT negative patients?
What is the role of focal therapy in PCa?
The evolving role of RT in localised PCa
Q&A
Broadening horizons in the management of CRPC
Genomic testing in advanced PCa: a pragmatic guide for clinicians
Where does Lu-PSMA fit in the treatment landscape?
How to deal with the conundrum of the 3rd line?
New agents on the horizon
Q&A
Best poster session
Interpretation of novel imaging for clinicians
Reading MRI for non-radiologists
Improve your PSMA-PET/CT reading skills
Q&A

PROSCA 2021

Day 2 – 13 October 2021

Opening day 2
Non-metastatic recurrence following therapy with curative intent
Clinical case discussions
Update lecture: immunotherapy in prostate cancer
From multi-disciplinary to multi-professional management
Update on pathology
View from the patient and specialised nurse
Q&A
How can AI improve outcomes of patients with prostate cancer
Radiogenomics of PCa
AI and real-world data: can they really replace RCTs?
AI and robotics: a combination that is changing the operating room
AI and radiotherapy
Q&A
APCCC 2021 highlights

PROSCA 2021

Day 2 – 13 October 2021

Opening day 2
Session 5
Non-metastatic recurrence following therapy with curative intent
 

Clinical case discussions

Update lecture: immunotherapy in prostate cancer
Session 6
From multi-disciplinary to multi-professional management

Update on pathology

View from the patient and specialised nurse

Q&A
Session 7
How can AI improve outcomes of patients with prostate cancer
Radiogenomics of PCa
AI and real-world data: can they really replace RCTs?
AI and robotics: a combination that is changing the operating room
AI and radiotherapy
Q&A
Session 8
APCCC 2021 highlights

BLADDR 2021

Day 1 – 14 October 2021

Official opening
Session 1
The new multidisciplinary world of NMIBC

Can we safely de-intensify the management of low/intermediate-risk NMIBC?

BCG-unresponsive bladder cancer

Clinical case discussion: Management of high-risk NMIBC

Q&A
Session 2
Metastatic UCa

Clinical case discussion: PD-L1-positive cisplatin-unfit patients with mUCa: chemo- or immunotherapy?

Will chemotherapy remain SOC as first-line therapy for all patients with mUCa?

Update on second- and further-line therapies for mUCa

Managing treatment-related AEs in patients with mUCa

Q&A
Session 3
Muscle-invasive bladder cancer
Perioperative systemic therapies in MIBC

Neoadjuvant chemotherapy before TMT: yes or no?

Robotical cystectomy

Q&A
Session 4
What really matters to patients for whom cystectomy is planned

Panel discussion

Session 5
Should UTUC and bladder carcinoma be treated the same or differently?
Diagnosis and surgical management of localised UTUC

Systemic therapy for advanced UTUC

Clinical case discussion

Q&A

BLADDR 2021

Day 1 – 14 October 2021

Official opening
The new multidisciplinary world of NMIBC
Can we safely de-intensify the management of low/intermediate-risk NMIBC?
BCG-unresponsive bladder cancer
Clinical case discussion: Management of high-risk NMIBC
Q&A
Metastatic UCa
Clinical case discussion: PD-L1-positive cisplatin-unfit patients with mUCa: chemo- or immunotherapy?
Will chemotherapy remain SOC as first-line therapy for all patients with mUCa?
Update on second- and further-line therapies for mUCa
Managing treatment-related AEs in patients with mUCa
Q&A
Muscle-invasive bladder cancer
Perioperative systemic therapies in MIBC
Neoadjuvant chemotherapy before TMT: yes or no?
Robotical cystectomy
Q&A
What really matters to patients for whom cystectomy is planned
Panel discussion
Should UTUC and bladder carcinoma be treated the same or differently?
Diagnosis and surgical management of localised UTUC
Systemic therapy for advanced UTUC
Clinical case discussion
Q&A

BLADDR 2021

Day 2 – 15 October 2021

Opening day 2
Clinical questions: what would you do?
Neoadjuvant or adjuvant treatment for a cisplatin-ineligible patient with MIBC
Should all patients with mUCa, having at least stable disease on first-line chemotherapy receive avelumab maintenance therapy?
Oligometastatic bladder cancer: when to consider treatment with curative intent?
Best poster session
Rare histologies and variants
Adenocarcinoma and small-cell carcinoma
Clinical case discussion
Future directions for optimal decision making
Are we ready for ctDNA triggered therapy?
Novel imaging in bladder cancer diagnosis and staging
Q&A

BLADDR 2021

Day 2 – 15 October 2021

Opening day 2
Session 6
Clinical questions: what would you do?

Neoadjuvant or adjuvant treatment for a cisplatin-ineligible patient with MIBC

Should all patients with mUCa, having at least stable disease on first-line chemotherapy receive avelumab maintenance therapy?

Oligometastatic bladder cancer: when to consider treatment with curative intent?

Best poster session
Session 7
Rare histologies and variants
Adenocarcinoma and small-cell carcinoma

Clinical case discussion

Session 8
Future directions for optimal decision making
Are we ready for ctDNA triggered therapy?

Novel imaging in bladder cancer diagnosis and staging

Q&A
Legend:
Lecture
Debate/ panel discussion
Q&A

Mirrors of Medicine

Organised by
ISSECAM

Congress management by
e-HIMS